{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:53:38Z","timestamp":1788587618230,"version":"build-2803163510"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100010937","name":"St. John\u2019s University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Epalrestat (EPS), an aldose reductase inhibitor, is widely prescribed to manage diabetic neuropathy. It is generally believed that EPS is beneficial to diabetic patients because it can protect endothelial cells, Schwann cells, or other neural cells from oxidative stress. However, several clinical studies revealed that EPS therapy led to liver dysfunction, which limited its clinical applications. Currently, the underlying mechanism by which EPS causes liver dysfunction is unknown. This study aimed to investigate the mechanism responsible for EPS-induced liver injury. In mouse liver, EPS 1) increased oxidative stress, indicated by increased expression of manganese superoxide dismutase, Ho-1, and Nqo1, 2) induced inflammation, indicated by infiltration of inflammatory cells, and induced expression of tumor necrosis factor-alpha, CD11b, and CD11c, as well as 3) predisposed to induce fibrosis, evidenced by increased mRNA and protein expression of early profibrotic biomarker genes procollagen I and alpha-smooth muscle actin, and by increased collagen deposition. In cultured mouse and human hepatoma cells, EPS treatment induced oxidative stress, decreased cell viability, and triggered apoptosis evidenced by increased Caspase-3 cleavage\/activation. In addition, EPS increased mRNA and protein expression of cytoglobin in mouse liver, indicating that EPS activated hepatic stellate cells (HSCs). Furthermore, EPS treatment in cultured human HSCs increased cell viability. In summary, EPS administration induced oxidative stress and inflammation in mouse liver, and stimulated liver fibrogenesis. Therefore, cautions should be exercised during EPS therapy.<\/jats:p>","DOI":"10.1093\/toxsci\/kfx038","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T08:57:36Z","timestamp":1487149056000},"page":"397-408","source":"Crossref","is-referenced-by-count":11,"title":["Epalrestat Stimulated Oxidative Stress, Inflammation, and Fibrogenesis in Mouse Liver"],"prefix":"10.1093","volume":"163","author":[{"given":"Yuan","family":"Le","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengli","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences"},{"name":"Department of Biological Sciences College of Liberal Arts and Sciences, St John\u2019s University, Queens, New York 11439"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoli","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Biology, Center for Developmental and Regenerative Biology, School of Science, Indiana University-Purdue University Indianapolis, Indianapolis, Indiana 46202"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingguo","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"2024041207490116300_kfx038-B1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"2024041207490116300_kfx038-B2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/emm.2001.31","article-title":"Chronic liver injury, TGF-beta, and cancer","volume":"33","author":"Bissell","year":"2001","journal-title":"Exp. Mol. Med."},{"key":"2024041207490116300_kfx038-B3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0891-8422(23)00518-9","article-title":"Drug therapy of diabetic neuropathy","volume":"9","author":"Brooks","year":"1992","journal-title":"Clin. Podiatr. Med. Surg."},{"key":"2024041207490116300_kfx038-B4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.taap.2014.04.013","article-title":"Fibroblast growth factor (Fgf) 21 is a novel target gene of the aryl hydrocarbon receptor (AhR)","volume":"278","author":"Cheng","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"2024041207490116300_kfx038-B5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-2007-1007105","article-title":"Cytokines and fibrogenesis","volume":"19","author":"Friedman","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"2024041207490116300_kfx038-B6","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0168-8278(02)00429-4","article-title":"Liver fibrosis \u2013 from bench to bedside","volume":"38(Suppl 1)","author":"Friedman","year":"2003","journal-title":"J. Hepatol."},{"key":"2024041207490116300_kfx038-B7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"2024041207490116300_kfx038-B8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2957\/kanzo.52.351","article-title":"Drug-induced hepatic injury caused by an aldose reductase inhibitor, epalrestat","volume":"52","author":"Fujise","year":"2011","journal-title":"Kanzo"},{"key":"2024041207490116300_kfx038-B9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev.me.26.020175.002513","article-title":"Hyperglycemia, polyol metabolism, and complications of diabetes mellitus","volume":"26","author":"Gabbay","year":"1975","journal-title":"Annu. Rev. Med"},{"key":"2024041207490116300_kfx038-B10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0753-3322(96)82642-4","article-title":"Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study","volume":"49","author":"Goto","year":"1995","journal-title":"Biomed. Pharmacother"},{"key":"2024041207490116300_kfx038-B11","first-page":"39S","article-title":"A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy","volume":"10(Suppl 2)","author":"Goto","year":"1993","journal-title":"Diabet. Med."},{"key":"2024041207490116300_kfx038-B12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2004.12.014","article-title":"Cholestatic hepatocellular injury: What do we know and how should we proceed","volume":"42","author":"Guicciardi","year":"2005","journal-title":"J. Hepatol."},{"key":"2024041207490116300_kfx038-B13","first-page":"89","article-title":"New concepts and insights on pathogenesis and treatment of diabetic complications: Polyol pathway and its inhibition","volume":"60","author":"Hotta","year":"1997","journal-title":"Nagoya J. Med. Sci"},{"key":"2024041207490116300_kfx038-B14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0014-4835(90)90104-3","article-title":"Current progress in clinical trials of aldose reductase inhibitors in Japan","volume":"50","author":"Hotta","year":"1990","journal-title":"Exp. Eye Res."},{"key":"2024041207490116300_kfx038-B15","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1464-5491.2008.02490.x","article-title":"Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat","volume":"25","author":"Hotta","year":"2008","journal-title":"Diabet. Med."},{"key":"2024041207490116300_kfx038-B16","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1464-5491.2012.03684.x","article-title":"Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: Multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy","volume":"29","author":"Hotta","year":"2012","journal-title":"Diabetic Med"},{"key":"2024041207490116300_kfx038-B17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/BF02191904","article-title":"Effects of propionyl-L-carnitine and insulin on the electroretinogram, nerve conduction and nerve blood flow in rats with streptozotocin-induced diabetes","volume":"431","author":"Hotta","year":"1996","journal-title":"Pflugers Arch"},{"key":"2024041207490116300_kfx038-B18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/1056-8727(96)00113-4","article-title":"Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: Multicenter study. Diabetic Neuropathy Study Group in Japan","volume":"10","author":"Hotta","year":"1996","journal-title":"J. Diabet. Complications"},{"key":"2024041207490116300_kfx038-B19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/10715769900300881","article-title":"Regulatory mechanisms of cellular response to oxidative stress","volume":"31","author":"Itoh","year":"1999","journal-title":"Free Radic. Res"},{"key":"2024041207490116300_kfx038-B20","first-page":"261","article-title":"Cell and tissue responses to oxidative damage","volume":"69","author":"Janssen","year":"1993","journal-title":"Lab. Invest"},{"key":"2024041207490116300_kfx038-B21","doi-asserted-by":"crossref","first-page":"25318","DOI":"10.1074\/jbc.M102630200","article-title":"Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells","volume":"276","author":"Kawada","year":"2001","journal-title":"J. Biol. Chem"},{"key":"2024041207490116300_kfx038-B22","first-page":"168","article-title":"Effects of aldose reductase inhibitor on the peripheral nerve function during ischemia in diabetics","volume":"70(Suppl 2)","author":"Kuriya","year":"1987","journal-title":"J. Med. Assoc. Thailand"},{"key":"2024041207490116300_kfx038-B23","doi-asserted-by":"crossref","DOI":"10.59720\/16-003","article-title":"Molecular alterations in a high-fat mouse model before the onset of diet-induced nonalcoholic fatty liver disease","author":"Lee","year":"2016","journal-title":"J. Emerg. Invest"},{"key":"2024041207490116300_kfx038-B24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/1673-5374.177745","article-title":"Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway","volume":"11","author":"Li","year":"2016","journal-title":"Neural Regen. Res"},{"key":"2024041207490116300_kfx038-B25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4196\/kjpp.2015.19.5.401","article-title":"Amelioration of bleomycin-induced pulmonary fibrosis of rats by an aldose reductase inhibitor, epalrestat","volume":"19","author":"Li","year":"2015","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"2024041207490116300_kfx038-B26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.toxlet.2008.09.015","article-title":"Localization and expression pattern of cytoglobin in carbon tetrachloride-induced liver fibrosis","volume":"183","author":"Man","year":"2008","journal-title":"Toxicol. Lett."},{"key":"2024041207490116300_kfx038-B27","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/j.diabres.2007.01.069","article-title":"A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT)","volume":"77(Suppl 1)","author":"Matsuoka","year":"2007","journal-title":"Diabetes Res. Clin. Pract"},{"key":"2024041207490116300_kfx038-B28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/labinvest.2013.135","article-title":"Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver","volume":"94","author":"Motoyama","year":"2014","journal-title":"Lab. Invest"},{"key":"2024041207490116300_kfx038-B29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.mpg.0000179758.82919.1f","article-title":"Liver histology and alanine aminotransferase levels in children and adults with chronic hepatitis C infection","volume":"41","author":"Murray","year":"2005","journal-title":"J. Pediatr. Gastroenterol. Nutr"},{"key":"2024041207490116300_kfx038-B30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0032-1333279","article-title":"Epalrestat improves diabetic wound healing via increased expression of nerve growth factor","volume":"121","author":"Nakagaki","year":"2013","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"2024041207490116300_kfx038-B31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0074-7742(02)50082-9","article-title":"Polyol pathway and diabetic peripheral neuropathy","volume":"50","author":"Oates","year":"2002","journal-title":"Int. Rev. Neurobiol"},{"key":"2024041207490116300_kfx038-B32","doi-asserted-by":"crossref","first-page":"789730.","DOI":"10.1155\/2012\/789730","article-title":"Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-alpha and ameliorates hepatosteatosis in diabetic db\/db mice","volume":"2012","author":"Qiu","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"2024041207490116300_kfx038-B33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1592\/phco.28.5.646","article-title":"Epalrestat: An aldose reductase inhibitor for the treatment of diabetic neuropathy","volume":"28","author":"Ramirez","year":"2008","journal-title":"Pharmacotherapy"},{"key":"2024041207490116300_kfx038-B34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.redox.2013.11.003","article-title":"Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation","volume":"2","author":"Sato","year":"2013","journal-title":"Redox Biology"},{"key":"2024041207490116300_kfx038-B35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4103\/0972-2327.44558","article-title":"Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective","volume":"11","author":"Sharma","year":"2008","journal-title":"Ann. Indian Acad. Neurol."},{"key":"2024041207490116300_kfx038-B36","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2165\/00002512-199303060-00007","article-title":"Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus","volume":"3","author":"Steele","year":"1993","journal-title":"Drugs Aging"},{"key":"2024041207490116300_kfx038-B37","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0149-2918(95)80111-1","article-title":"Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus","volume":"17","author":"Uchida","year":"1995","journal-title":"Clin. Ther."},{"key":"2024041207490116300_kfx038-B38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2015.11.012","article-title":"Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-beta\/smad2\/3 and NF-kappaB signaling pathways","volume":"290","author":"Xu","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"2024041207490116300_kfx038-B39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.redox.2014.12.002","article-title":"Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells","volume":"4","author":"Yama","year":"2015","journal-title":"Redox Biol."},{"key":"2024041207490116300_kfx038-B40","doi-asserted-by":"crossref","DOI":"10.1248\/bpb.b16-00332","article-title":"Epalrestat upregulates heme oxygenase-1, superoxide dismutase, and catalase in cells of the nervous system","author":"Yama","year":"2016","journal-title":"Biol. Pharm. Bull"},{"key":"2024041207490116300_kfx038-B41","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/hep.27060","article-title":"Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1alpha-mediated antioxidant capacity in mice","volume":"60","author":"Ye","year":"2014","journal-title":"Hepatology"},{"key":"2024041207490116300_kfx038-B42","doi-asserted-by":"crossref","first-page":"33102.","DOI":"10.1038\/srep33102","article-title":"Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid beta-oxidation","volume":"6","author":"Ye","year":"2016","journal-title":"Sci. Rep."},{"key":"2024041207490116300_kfx038-B43","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/abbs\/gmu097","article-title":"FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway","volume":"46","author":"Zhu","year":"2014","journal-title":"Acta Biochim. Biophys. Sin."}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/163\/2\/397\/57219864\/toxsci_163_2_397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/163\/2\/397\/57219864\/toxsci_163_2_397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T07:49:32Z","timestamp":1712908172000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/163\/2\/397\/2997454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,15]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfx038","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"value":"1096-6080","type":"print"},{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2017,2,15]]}}}